Literature DB >> 23019275

Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study.

E Marie Freel1, Patrick B Mark, Robin A P Weir, Emily P McQuarrie, Karen Allan, Henry J Dargie, John D McClure, Alan G Jardine, Eleanor Davies, John M C Connell.   

Abstract

BACKGROUND: Primary aldosteronism (PA) is common and associates with excess cardiovascular morbidity independent of blood pressure. Exposure to aldosterone and sodium leads to cardiac fibrosis and hypertrophy in humans and animals possibly mediated by inflammation and oxidative stress. We aimed to clarify the effects of aldosterone excess on myocardial structure and composition in human subjects with PA and essential hypertension using contrast-enhanced cardiac magnetic resonance imaging as well as explore the mechanistic basis for any observed differences. METHODS AND
RESULTS: Twenty-seven subjects with recently diagnosed PA and 54 essential hypertension controls were recruited. Subjects underwent gadolinium-enhanced cardiac magnetic resonance; noninfarct related myocardial fibrosis was identified by a diffuse pattern of late gadolinium enhancement. Patients also underwent assessment of pulse wave velocity, measurement of circulating superoxide anion and C-reactive protein, as well as blood pressure and biochemical assessment. Subjects were well matched with no difference in severity or duration of hypertension. There was a significant increase in the frequency of noninfarct late gadolinium enhancement in PA (70%) when compared with essential hypertension subjects (13%; P<0.0001) with no difference in left ventricular mass. Pulse wave velocity, superoxide, and C-reactive protein were significantly higher in subjects with PA.
CONCLUSIONS: These data illustrate that patients with PA exhibit frequent myocardial fibrosis as demonstrated by late gadolinium enhancement using cardiac magnetic resonance imaging; this finding is independent of blood pressure. This may be mediated partly through inflammation and oxidative stress. This study highlights the importance of specific targeting of aldosterone excess as well as blood pressure reduction to minimize cardiac morbidity in PA.

Entities:  

Mesh:

Year:  2012        PMID: 23019275     DOI: 10.1161/CIRCIMAGING.112.974576

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  22 in total

1.  Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study.

Authors:  P B Mark; S Boyle; L U Zimmerli; E P McQuarrie; C Delles; E M Freel
Journal:  J Hum Hypertens       Date:  2013-07-25       Impact factor: 3.012

2.  Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry.

Authors:  A Grotevendt; H Wallaschofski; M Reincke; C Adolf; M Quinkler; M Nauck; W Hoffmann; R Rettig; A Hannemann
Journal:  Endocrine       Date:  2017-06-22       Impact factor: 3.633

Review 3.  Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.

Authors:  Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2022-09-22       Impact factor: 2.877

Review 4.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 5.  Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.

Authors:  Augusto C Montezano; Rhian M Touyz
Journal:  Antioxid Redox Signal       Date:  2013-06-06       Impact factor: 8.401

Review 6.  Primary Aldosteronism: a Continuum from Normotension to Hypertension.

Authors:  Taweesak Wannachalee; Adina F Turcu
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

7.  A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: Proof of concept? The VaSera trial testing dietary nitrate and spironolactone.

Authors:  Charlotte E Mills; Virginia Govoni; Luca Faconti; Maria-Linda Casagrande; Steven V Morant; Hannah Crickmore; Fahad Iqbal; Perry Maskell; Alisha Masani; Elisa Nanino; Andrew J Webb; J Kennedy Cruickshank
Journal:  Br J Clin Pharmacol       Date:  2020-02-22       Impact factor: 4.335

Review 8.  Left ventricular remodeling and dysfunction in primary aldosteronism.

Authors:  Cheng-Hsuan Tsai; Chien-Ting Pan; Yi-Yao Chang; Zheng-Wei Chen; Vin-Cent Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Hum Hypertens       Date:  2020-10-16       Impact factor: 3.012

9.  Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.

Authors:  Adina F Turcu; Richard Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

10.  CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients.

Authors:  Fangli Zhou; Tao Wu; Wei Wang; Wei Cheng; Shuang Wan; Haoming Tian; Tao Chen; Jiayu Sun; Yan Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.